Search

Displaying results 1181 - 1190 of 2494 in total
  1. Drug

    Pazufloxacin

    go.drugbank.com/drugs/DB11774
    Investigational

    Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  2. Drug

    Allicin

    go.drugbank.com/drugs/DB11780
    Investigational

    Allicin has been used in trials studying the treatment of Follicular Lymphoma.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  3. Drug

    Relugolix

    go.drugbank.com/drugs/DB11853
    ApprovedInvestigational

    Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment...

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates
  4. Drug

    Valspodar

    go.drugbank.com/drugs/DB11869
    Investigational

    Valspodar has been used in trials studying the treatment of Cancer, Sarcoma, Leukemia, Lymphoma, and Breast Cancer, among others.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  5. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the tr...

    Categories: P-glycoprotein inducers, Cytochrome P-450 CYP2C19 Inducers
  6. Drug

    6-O-benzylguanine

    go.drugbank.com/drugs/DB11919
    Investigational

    6-O-benzylguanine has been used in trials studying the treatment of HIV Infection, Adult Gliosarcoma, Adult Glioblastoma, Stage I Adult Hodgkin Lymphoma, and Stage II Adult Hodgkin Lymphoma, among others.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  7. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed fro...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain o...

    Categories: Cytochrome P-450 CYP2C9 Substrates, P-glycoprotein inhibitors
  9. Drug

    SJG-136

    go.drugbank.com/drugs/DB11965
    Investigational

    SJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and Secondary Myelodysplastic Syndromes,...

    Categories: P-glycoprotein substrates
  10. Drug

    Binimetinib

    go.drugbank.com/drugs/DB11967
    ApprovedInvestigational

    Binimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with Encorafenib. On June 27, 2018, the Food and Drug Administration approved the combination o...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates